Clinical trials: Psoriasis (PsO)
Psoriatic Arthritis, Psoriasis (PsO)
Inflammation Digital Biomarkers Validation Study
HIPPOCRATES is an Innovative Medicines Initiative (IMI) funded EU Consortium established to address key unmet clinical needs in psoriatic disease.
- Trial name
- IDBV (NCT07594054)
- Volunteers
- 3,458 people
- Sponsor
- University of Oxford
Psoriasis, Psoriasis Arthritis
Psoriasis Comorbidities at Hospital Calderón Guardia
The goal of this observational study is to characterize the epidemiologic, clinical, severity, and therapeutic features of patients with psoriasis treated in Costa Rica between 2024 and 2025.
- Conditions
- Psoriasis, Psoriasis Arthritis, Psoriasis (PsO), Psoriasis Patients
- Trial name
- NCT07448337
- Where
- Costa Rica
- Volunteers
- 350 people
- Sponsor
- Caja Costarricense de Seguro Social
Psoriasis (PsO)
A Study to Assess Deucravacitinib Safety in Pregnancy
The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists [OTIS]) who were…
- Trial name
- NCT07017699
- Testing
- Deucravacitinib, Other systemic treatments for PsO
- Where
- United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Psoriasis (PsO)
Global Healthcare Study on Psoriasis
The Global Healthcare Study on Psoriasis (GHSP) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of…
- Trial name
- GHSP (NCT07634016)
- Where
- Switzerland
- Volunteers
- 9,600 people
- Sponsor
- Julia Tatjana Maul
Autoimmune Diseases, Rheumatoid Arthritis (RA)
A Trial of Academic Detailing to Promote Prescribing of Biosimilars
The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1.
- Conditions
- Autoimmune Diseases, Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), Psoriasis (PsO)
- Trial name
- NCT07221890
- Testing
- Offered an academic detailing session, Standard-of-care outreach from the insurance plan
- Where
- 2 sites in United States
- Volunteers
- 1,325 people
- Sponsor
- Brigham and Women's Hospital
Psoriasis, Psoriasis Arthritis
Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
The goal of this observational registry study is to evaluate the real-world effectiveness and safety of IL-23 inhibitors in patients with psoriatic disease (psoriasis and/or psoriatic arthritis) treated in Costa Rica.
- Conditions
- Psoriasis, Psoriasis Arthritis, Psoriasis (PsO)
- Trial name
- NCT07448402
- Testing
- Guselkumab (GUS), Risankizumab (RISA)
- Where
- Costa Rica
- Volunteers
- 50 people
- Sponsor
- Caja Costarricense de Seguro Social
Moderate to Severe Plaque Psoriasis
A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).
- Trial name
- BE CONNECTED (NCT04718896)
- Testing
- bimekizumab
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 41 people
- Sponsor
- UCB Biopharma SRL
Moderate to Severe Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to <18 years of age with moderate to severe…
- Trial name
- BE TOGETHER (NCT06425549)
- Testing
- bimekizumab, ustekinumab
- Where
- 42 sites in United States, Belgium and 8 more
- Volunteers
- 176 people
- Sponsor
- UCB Biopharma SRL
Systemic Lupus Erythematosus, Sjögren's Disease
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Psoriasis, Psoriatic Arthritis
- Trial name
- NCT07791199
- Testing
- Deucravacitinib
- Volunteers
- 2,300 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis
- Trial name
- POETYK-PsO-Ped (NCT06979453)
- Testing
- Deucravacitinib
- Where
- 133 sites in United States, Argentina and 14 more
- Volunteers
- 366 people
- Sponsor
- Bristol-Myers Squibb